The protective effect of albumin on bevacizumab activity and stability in PLGA nanoparticles intended for retinal and choroidal neovascularization treatments

• Published in: European journal of pharmaceutical sciences Vol. 50; no. 3-4; pp. 341 - 352
• Main Authors: Varshochian, Reyhaneh, Jeddi-Tehrani, Mahmood, Mahmoudi, Ahmad Reza, Khoshayand, Mohammad Reza, Atyabi, Fatemeh, Sabzevari, Araz, Esfahani, Mohammad Riazi, Dinarvand, Rassoul
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 20.11.2013
• Subjects: Albumin; Angiogenesis Inhibitors - chemistry; Angiogenesis Inhibitors - pharmacology; Animals; Antibodies, Monoclonal, Humanized - chemistry; Antibodies, Monoclonal, Humanized - pharmacology; Bevacizumab; Choroidal Neovascularization - drug therapy; Drug Stability; Immunoglobulin G - immunology; Lactic Acid - chemistry; Medicin och hälsovetenskap; Monoclonal antibody stability; Nanoparticles - chemistry; Ophthalmic drug delivery; PLGA nanoparticles; Polyglycolic Acid - chemistry; Rabbits; Retinal Neovascularization - drug therapy; Serum Albumin - chemistry; Vascular Endothelial Growth Factor A - metabolism; Vitreous Body - metabolism; Albumin; Ophthalmic drug delivery; Monoclonal antibody stability; PLGA nanoparticles; Bevacizumab

The paper showed incorporation of albumin within the aqueous phase of primary emulsion in double emulsion method could protect bevacizumab from emulsification drawbacks during entrapment into PLGA nanoparticles. It has been assumed that albumins prevent bevacizumab interfacial-adsorption by competit...